去纤苷的不良反应有哪些？

Defibrotide (defiteli) is a biochemical drug derived from a mixture of single-stranded deoxyoligonucleotides. It mainly acts on endothelial cells and produces a variety of biological effects. Clinical research is mainly carried out around the indications of cardiovascular dysfunction. Clinical experiments have proven that defibrotide can effectively prevent and treat hepatic veno-occlusive disease (VOD). So, what are the adverse reactions of defibrotide (defiteli)? Let's take a look.

Adverse reactions of defibrotide (defiteli sodium, defiteli):

In clinical trials, the most common adverse reactions (incidence ≥10% and independent causal relationship) of defibrotide (defiteli) were hypotension, diarrhea, vomiting, nausea, and epistaxis. The most common serious adverse reactions (incidence ≥5% and independent causal relationship) were hypotension (11%) and alveolar hemorrhage (7%). Bleeding events of any type and any grade were reported in 104 (59%) patients, and in 35 (20%) the events were grade 4-5.

Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide (defiteli). These reactions include rash, urticaria, and angioedema. A case of allergic reaction was reported in a patient who had previously received defiteli. Monitor patients for hypersensitivity reactions. Especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue defiteli, treat with standard medical care, and monitor until symptoms resolve.

Clinical studies of defiteli did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently than younger subjects. Other reported clinical experience has not identified differences in response between older and younger patients. There are no known cases of overdose with defiteli. There are no known antitoxicants for defibrotide, and defibrotide (defiteli) is not dialyzable. If overdose occurs, initiate general supportive measures.

There are not many adverse reactions of defibrotide (defiteli), but patients should not change the method of taking it without permission, and should use the medicine strictly in accordance with the instructions.